Rovi stock sits 32.30 percent below its 52-week high

Published on 10/21/2026 at 09:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi reported EUR 344.20 million in first-half 2026 operating revenue. Rovi stock costs EUR 58.65 on October 21, 2026, below its EUR 86.70 high.

Operating growth and reporting date

Rovi reported EUR 344.20 million in operating revenue for the first half of 2026.
Rovi expects to publish its first nine months 2026 results on November 5, 2026.
Rovi stock traded at EUR 58.65 at 9:36 a.m. CEST at Lang & Schwarz on October 21, 2026.

Rovi, ES0157261019, Illustration mit AI erstellt.

Laboratorios Farmaceuticos Rovi (ISIN ES0157261019) was trading at EUR 58.65 at Lang & Schwarz on October 21, 2026 at 9:36 a.m. CEST, 32.30 percent below its EUR 86.70 52-week high. The company's investor calendar points to first nine months 2026 results on November 5, 2026, giving the stock a defined near-term reporting catalyst.

First-half growth sets the baseline

Rovi reported EUR 344.20 million in operating revenue for the first half of 2026, up 9.40 percent from the same period of 2025. Contract development and manufacturing revenue rose 38.00 percent to EUR 106.30 million, making that business the clearest quantified growth engine in the interim figures.

The first-half net profit was EUR 84.40 million, compared with EUR 39.70 million a year earlier. Estrategias de Inversion reported that the result included EUR 62.40 million of nonrecurring badwill from the Phoenix plant acquisition, so the earnings comparison needs that one-off item in its interpretation.

Three dates frame the stock

On May 6, 2026, Rovi reported EUR 154.70 million of first-quarter revenue; on July 23, 2026, it reported EUR 344.20 million of first-half operating revenue; on October 21, 2026, its Lang & Schwarz quote stood at EUR 58.65. The sequence moves from operating performance to the next market reference.

What does the next report test?

The November 5, 2026 release will test whether the first-half growth mix is carrying into the nine-month period. Rovi's 2026 outlook calls for operating revenue growth between 0.00 percent and 10.00 percent, while the company also highlighted pressure from heparin pricing and a delayed prefilled-syringe contract.

Stock remains below its yearly high

Rovi stock was 32.30 percent below its EUR 86.70 52-week high at the Lang & Schwarz quote, leaving the November report as the next dated checkpoint for the revenue trajectory.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.